Multiple Chemistry42-designed compounds have been identified and developed for various clinical indications, e.g., inhibitors targeting TNIK (idiopathic pulmonary fibrosis), USP1 (BRACMut cancer), MAT2A (MTAP−/− cancer), KAT6 (ER+/Her2− breast cancer), KIF18A (chromosome unstable cancer), ENPP1, TEAD, DGKA, CDK12/13, FGFR2/3, and cMYC (solid tumors) (https://insilico.com/pipeline, accessed on 23 May 2025). This evidence concerns the gene FGFR2 and cancer.